EGFR and pachyonychia congenita: Erlotinib (ERL), an FDA-approved EGFR inhibitor, has shown therapeutic effect in the treatment of PC when used in combination with gemcitabine (Sinn et al., 2017; Halfdanarson et al., 2019).